Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

MacroGenics, Inc.

35 indications, side-by-side phase, drug & LoA

$3.96

-0.05 (-1.25%)

B 68Pipeline Score Undervalued Pharma · Commercial
Market Cap
287.94 M
EPS
-1.11
P/E Ratio
-
Value Trade
2.62 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    20.77 M

  • R&D Expenses

    34.97 M

  • Operating CF

    -35.81 M

  • Total Assets

    217.87 M

  • Total Liabilities

    196.68 M

  • Equity

    21.20 M

  • D/E Ratio

    12,345

9.69 %
Week
28.69 %
1 Month
163.37 %
3 Month
230.66 %
6 Month
-85.15 %
5 Year
-81.13 %
All Time
Cash Data
Stable

  • Cash Position

    154.23 M

  • Monthly Burn

    11.94 M

  • Runway

    12 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
513.19 K
52 Week Range
1.19 - 4.64
% held by Insiders
3.54 %
% held by Institutions
70.1 %
Enterprise Value
238.93 M
Total Shares
63.23 M
Short %
8.09 %
Float Shares
61.53 M
Company Description
HQ: 9704 MEDICAL CENTER DRIVE, Roc...
Employees:293
https://www.macrogenics.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout example
MGC026 selected solid tumor indications
Phase 1
—
Antibody-Drug Conjugates (ADCs)
Oncology
MGC026 selected solid tumor indications
Phase 1
—
Antibody-Drug Conjugates (ADCs)
Oncology
MGC026 selected solid tumor indications
Phase 1
—
Antibody-Drug Conjugates (ADCs)
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B68
Pipeline Score
$3.3B
Pipeline Value
Undervalued
Valuation Signal
21
Drugs Scored
11.4x
rNPV / MCap
Top 93%
Micro Cap
(rank 64 of 905)
Percentile Rank
MacroGenics, Inc. holds a solid B-grade pipeline (68/100), with $23.7B risk-adjusted pipeline value, led by Lorigerlimab in Metastatic Cancer (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Lorigerlimab
Small molecule		Pancreatic AdenocarcinomaPhase 2NCT0756515519% $7.7B NOT YET_RECRUITING 40 - -Jun 1, 2031 -LOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in MGNX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MGNX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGNX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGNX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
MGNX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
MGNX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest MacroGenics, Inc. (MGNX) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How MGNX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Cervical Cancer #6 of 30 PHASE 2 Lorigerlimab
AZN MRK PFE
$8.88B 0.66 FOLLOWER
Rare Hematological Disorders #11 of 17 PHASE 1 MGD024
AZN NVS VRTX
—0.9 FOLLOWER
Endometrial Cancer #14 of 46 PHASE 2 Lorigerlimab
MRK AZN GILD
$31.09B 0.66 FOLLOWER
Cholangiocarcinoma #18 of 24 PHASE 1 MGC028
AZN JAZZ LLY
$0.62B 0.66 FOLLOWER
Sarcoma #23 of 30 PHASE 1 MGC026 Dose Escalation
NVS INTS LLY
$1.75B 0.55 FOLLOWER
Ovarian Cancer #24 of 60 PHASE 2 Lorigerlimab
MRK AZN LLY
$4.11B 0.66 FOLLOWER
Myelodysplastic Syndromes #25 of 33 PHASE 1 MGD024
BMY ABBV TAK
$2.5B 0.9 FOLLOWER
Kidney Cancer #28 of 38 PHASE 1 MGC026 Dose Escalation
BMY MRK AZN
$7.31B 0.55 FOLLOWER
Esophageal Cancer #29 of 39 PHASE 1 MGC026 Dose Escalation
AZN MRK ONC
$1.85B 0.55 FOLLOWER
Liver Cancer #29 of 37 PHASE 1 MGC026 Dose Escalation
AZN BMY EXEL
$4.8B 0.55 FOLLOWER
Gastric Cancer #36 of 49 PHASE 1 MGC026 Dose Escalation
AZN ONC JAZZ
$6.74B 0.55 FOLLOWER
Prostate Cancer #37 of 53 PHASE 1 MGC026 Dose Escalation
MRK AZN PFE
$25.12B 0.55 FOLLOWER
Bladder Cancer #37 of 47 PHASE 1 MGC026 Dose Escalation
AZN BMY JNJ
$0.33B 0.55 FOLLOWER
Melanoma #41 of 52 PHASE 1 MGC026 Dose Escalation
MRK BMY REGN
$10.5B 0.55 FOLLOWER
Pancreatic Cancer #42 of 72 PHASE 1 MGC028
RVMD RCUS AZN
$3.7B 0.61 FOLLOWER
Head and Neck Cancer #44 of 62 PHASE 1 MGC026 Dose Escalation
AZN GSK JNJ
$10.2B 0.55 FOLLOWER
Leukemia #47 of 64 PHASE 1 MGD024
AMGN MRK LLY
$4.28B 0.9 FOLLOWER
Lymphoma #48 of 69 PHASE 1 MGD024
REGN LLY AZN
$8.52B 0.9 FOLLOWER
Colorectal Cancer #48 of 82 PHASE 1 MGC028
ABBV BMY MRK
$7.68B 0.61 FOLLOWER
Lung Cancer #55 of 78 PHASE 1 MGC028
MRK GILD AMGN
$28.1B 0.61 FOLLOWER
Breast Cancer #61 of 94 PHASE 1 MGC026 Dose Escalation
AZN MRK LLY
$10.85B 0.55 FOLLOWER
Non-Small Cell Lung Cancer #70 of 88 PHASE 1 MGC026 Dose Escalation
MRK AZN RVMD
$28.1B 0.55 FOLLOWER